About Proniras
Proniras is a company based in Seattle (United States) founded in 2018.. Proniras has raised $11.23 million across 3 funding rounds from investors including Arch Venture Partners, Accelerator and Watson Fund. The company has 2 employees as of December 31, 2021. Proniras offers products and services including Tezampanel and Novel Treatment for Opiate Withdrawal. Proniras operates in a competitive market with competitors including Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Ischemix and Edge Therapeutics, among others.
- Headquarter Seattle, United States
- Employees 2 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Proniras Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$11.23 M (USD)
in 3 rounds
-
Latest Funding Round
$6.93 M (USD), Series B
Dec 15, 2023
-
Investors
Arch Venture Partners
& 4 more
-
Employee Count
2
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Proniras
Proniras offers a comprehensive portfolio of products and services, including Tezampanel and Novel Treatment for Opiate Withdrawal. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for seizure disorders through development programs
Phase 1 study for addressing opiate withdrawal symptoms
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Proniras
Proniras has successfully raised a total of $11.23M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $6.93 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $6.9M
-
First Round
First Round
(11 Jul 2019)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Series B - Proniras | Valuation | Accelerator Life Science Partners , Arch Venture Partners | |
| Sep, 2020 | Amount | Grant - Proniras | Valuation |
investors |
|
| Jul, 2019 | Amount | Series A - Proniras | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Proniras
Proniras has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Arch Venture Partners, Accelerator and Watson Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital services are offered for early-stage biotech companies.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Early-stage venture capital is provided to US companies across sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Proniras
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Proniras
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Proniras Comparisons
Competitors of Proniras
Proniras operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Ischemix and Edge Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Next-generation medicines for CNS and immunological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic solution for the repair of cut and crushed peripheral nerves.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for retina and brain diseases
|
|
| domain | founded_year | HQ Location |
Developer of cytoprotective therapy for traumatic brain injury
|
|
| domain | founded_year | HQ Location |
Novel therapies for acute neurological conditions are developed and commercialized.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Proniras
Frequently Asked Questions about Proniras
When was Proniras founded?
Proniras was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Proniras located?
Proniras is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Proniras a funded company?
Proniras is a funded company, having raised a total of $11.23M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4.3M, raised on Jul 11, 2019.
How many employees does Proniras have?
As of Dec 31, 2021, the latest employee count at Proniras is 2.
What does Proniras do?
Proniras was founded in 2018 and is located in Seattle, United States. Small molecules are being developed by the company as medical countermeasures against seizures and brain injury from organophosphorus nerve agents. The lead candidate, tezampanel, functions as an AMPAkainate receptor antagonist and is advanced in the preclinical stage for parenteral administration. Development status was reported as preclinical in February 2019.
Who are the top competitors of Proniras?
Proniras's top competitors include Tonix Pharma, Neuraptive and Neurexis Therapeutics.
What products or services does Proniras offer?
Proniras offers Tezampanel and Novel Treatment for Opiate Withdrawal.
Who are Proniras's investors?
Proniras has 5 investors. Key investors include Arch Venture Partners, Accelerator, Watson Fund, Washington Research Foundation, and National Institute on Drug Abuse.